A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria

BACKGROUND: Tafenoquine is an investigational 8-aminoquinoline for the prevention of Plasmodium vivax relapse. Tafenoquine has a long half-life and the potential for more convenient dosing, compared with the currently recommended 14-day primaquine regimen. METHODS: This randomized, active-control, d...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuda, Mark M., Krudsood, Srivicha, Mohamed, Khadeeja, Green, Justin A., Warrasak, Sukhuma, Noedl, Harald, Euswas, Ataya, Ittiverakul, Mali, Buathong, Nillawan, Sriwichai, Sabaithip, Miller, R. Scott, Ohrt, Colin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679603/
https://www.ncbi.nlm.nih.gov/pubmed/29121061
http://dx.doi.org/10.1371/journal.pone.0187376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679603/
https://www.ncbi.nlm.nih.gov/pubmed/29121061
http://dx.doi.org/10.1371/journal.pone.0187376

Ejemplares similares